Novartis Price Fair Value from 2010 to 2024

NVS Stock  USD 104.28  0.43  0.41%   
Novartis Price Fair Value yearly trend continues to be comparatively stable with very little volatility. Price Fair Value will likely drop to 3.23 in 2024. From the period from 2010 to 2024, Novartis Price Fair Value quarterly data regression had r-value of  0.27 and coefficient of variation of  33.80. View All Fundamentals
 
Price Fair Value  
First Reported
2010-12-31
Previous Quarter
4.51992615
Current Value
3.23
Quarterly Volatility
1.01264199
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 B, Interest Expense of 550.6 M or Selling General Administrative of 15 B, as well as many indicators such as Price To Sales Ratio of 3.86, Dividend Yield of 0.0241 or PTB Ratio of 3.23. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.
  
Check out the analysis of Novartis Correlation against competitors.

Latest Novartis' Price Fair Value Growth Pattern

Below is the plot of the Price Fair Value of Novartis AG ADR over the last few years. It is Novartis' Price Fair Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.
Price Fair Value10 Years Trend
Pretty Stable
   Price Fair Value   
       Timeline  

Novartis Price Fair Value Regression Statistics

Arithmetic Mean3.00
Geometric Mean2.85
Coefficient Of Variation33.80
Mean Deviation0.81
Median2.81
Standard Deviation1.01
Sample Variance1.03
Range3.45
R-Value0.27
Mean Square Error1.02
R-Squared0.07
Significance0.33
Slope0.06
Total Sum of Squares14.36

Novartis Price Fair Value History

2024 3.23
2023 4.52
2022 3.32
2021 2.92
2020 3.8
2019 3.92
2018 2.23

About Novartis Financial Statements

Novartis shareholders use historical fundamental indicators, such as Price Fair Value, to determine how well the company is positioned to perform in the future. Although Novartis investors may analyze each financial statement separately, they are all interrelated. The changes in Novartis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Novartis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Price Fair Value 4.52  3.23 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.